The DSRU and the Future of UK Pharmacoepidemiology & Pharmacovigilance
3 December 2021
The DSRU has expanded enormously in the last few years. As the UK’s premier unit for pharmacoepidemiology and pharmacovigilance, we have a full understanding of the special characteristics of the UK population and National Health Service which means that the DSRU is ideally placed to conduct UK observational studies. The Unit has recently conducted many studies for a range of medicinal products, including an antidiabetic, analgesics, a flu vaccine and drugs to treat neurological disorders. We conduct studies for products for the top ten pharma companies in the world, as well as small to middle sized companies. The DSRU rose to the challenge of the COVID-19 pandemic by conducting studies on all the vaccines used in the UK, but this is just a small part of our range of activities. The DSRU’s experienced team can provide:
risk minimisation (both recommending RM measures and monitoring their effectiveness)
drug utilisation studies
quality of life studies
and much more.
We are very proud that the DSRU with its world-class team of epidemiologists, physicians and scientists has become the leading organisation in the UK for pharmacovigilance and pharmacoepidemiolgy. Our track record speaks for itself.